NCT00245765

Efficacy Study of CDP870 in Subjects With Chronic Plaque Psoriasis Who Are Candidate for Systemic Therapy and/or Phototherapy/Photochemotherapy

Multicenter, Dose Response, Randomized, Double Blind, Parallel, Placebo Controlled Clinical Trial to Evaluate the Efficacy and the Safety of Subcutaneous CDP870 in Subjects Suffering From Moderate-to-severe Chronic Plaque Psoriasis Who Are Candidates for Systemic Therapy and/or Phototherapy and/or Photochemotherapy

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 176 (actual)
• Sponsor: UCB Pharma · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

A study to assess the safety and efficacy of 2 different doses of CDP870 versus placebo, administered during 12 weeks, to patients suffering from moderate to severe chronic plaque psoriasis, extended by a 12 to 24 week follow-up.

Conditions

• Chronic Plaque Psoriasis

Interventions

Type	Name	Description
DRUG	Certolizumab Pegol	* Pharmaceutical Form: solution for injection in pre-filled syringe * Route of Administration: subcutaneous use
OTHER	Placebo	Matching Placebo to Certolizumab Pegol

Timeline

• Start date: 2005-10-01
• Primary completion: 2006-11-01
• Completion: 2006-11-01
• First posted: 2005-10-28
• Last updated: 2019-05-03
• Results posted: 2019-05-03

Locations

15 sites across 2 countries: France, Germany